<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 AM</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>8:20 AM</td>
<td>Welcome</td>
<td><strong>Jenny Chang, MD</strong>&lt;br&gt;Emily Herrmann Presidential Distinguished Chair in Cancer Research &amp; Director, Dr. Mary and Ron Neal Cancer Center Professor of Medicine, Academic Institute Full Member, Research Institute Houston Methodist Weill Cornell Medical College</td>
</tr>
<tr>
<td>8:30 AM</td>
<td>Solid Tumor Keynote: 30 years Perspective On Advanced Prostate Cancer: Using Biology &amp; Perseverance to Conquer New Frontiers</td>
<td><strong>Maha Hussain, MD, FACP, FASCO</strong>&lt;br&gt;Genevieve Teuton Professor of Medicine, Division of Hematology-Oncology Department of Medicine Deputy Director, GU Oncology Program Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine</td>
</tr>
<tr>
<td>9:15 AM</td>
<td>Question and Answer Session</td>
<td></td>
</tr>
<tr>
<td>9:25 AM</td>
<td>Whole-Body MRI – Past, Present and Future</td>
<td><strong>Nakul Gupta, MD</strong>&lt;br&gt;Assistant Professor of Clinical Radiology, Academic Institute&lt;br&gt;Assistant Clinical Member, Research Institute&lt;br&gt;Program Director, Abdominal Imaging Fellowship, Department of Radiology&lt;br&gt;Vice-Chair of Translational Imaging, Department of Radiology&lt;br&gt;Houston Methodist&lt;br&gt;Weill Cornell Medical College</td>
</tr>
<tr>
<td>9:55 AM</td>
<td>Question and Answer Session</td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Break and Exhibits</td>
<td></td>
</tr>
<tr>
<td>10:25 AM</td>
<td>Biology-Driven De-Escalation of Therapy in HER2+ Breast Cancer</td>
<td><strong>Polly A. Niravath, MD</strong>&lt;br&gt;Lois E. and Carl A. Davis Centennial Associate Professor in Cancer Research, Dr. Mary and Ron Neal Cancer Center Associate Professor of Clinical Medicine, Academic Institute Houston Methodist Weill Cornell Medical College</td>
</tr>
<tr>
<td>10:55 AM</td>
<td>Question and Answer Session</td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Novel Epigenetic Markers in Cell-free DNA of Cancer</td>
<td><strong>Zejuan Li, MD, PhD, FACMG</strong>&lt;br&gt;Associate Professor of Pathology and Genomic Medicine, Academic Institute&lt;br&gt;Associate Clinical Member, Research Institute Houston Methodist Weill Cornell Medical College</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Question and Answer Session</td>
<td></td>
</tr>
<tr>
<td>11:35 AM</td>
<td>Lunch Keynote I: Voices Heard: Music Therapy Within Oncology</td>
<td><strong>Sarah Rossi, MM, MT-BC</strong>&lt;br&gt;Board Certified Music Therapist&lt;br&gt;Center for Performing Arts Medicine Houston Methodist</td>
</tr>
<tr>
<td>12:05 PM</td>
<td>Lunch Keynote II: Palliative Medicine in Cancer Patients</td>
<td><strong>Elaine De Leon, MD</strong>&lt;br&gt;Hospice and Palliative Care&lt;br&gt;Houston Methodist Supportive &amp; Palliative Care Houston Methodist</td>
</tr>
<tr>
<td>12:35 PM</td>
<td>Lunch and Exhibits</td>
<td></td>
</tr>
</tbody>
</table>
### PROGRAM OVERVIEW

This annual symposium, dedicated to the science and clinical care of solid and hematologic malignancies, brings together Houston Methodist scientists and physicians from a broad spectrum of fields, including basic, clinical and epidemiological research. A wide range of topics will be covered, from innovative translational science to clinical updates with strategies for implementation in current clinical practice. The program will provide education focused on improving patient care, research collaboration and leading medicine.

### TARGET AUDIENCE

Physician scientists, practicing oncologists, advanced nurse practitioners and physician assistants, oncology nurses, residents, fellows, medical students, allied health personnel and clinical research associates will benefit from this course.

### EDUCATIONAL OBJECTIVES

Upon completion of this course, the participant should be able to:

- Discuss the fundamental mechanisms of cellular immunotherapy in hematologic malignancies
- Describe the approved cell therapy options in hematologic malignancies including CAR-T cell
- Identify new cellular therapies in the pipeline for these diseases

### NURSING OUTCOMES STATEMENT

Registered nurses attending this activity will report being better prepared to provide high quality evidence-based care including education and anticipatory guidance to patients with cancer based on the enhanced knowledge of emerging cancer therapies, particularly cellular therapy. They will identify at least one new learning related to cancer therapies that intend to incorporate into personal practice.

### EDUCATIONAL METHODS

Didactic Lectures, Question and Answer Sessions

---

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 1:00 PM| Hematology Keynote: CAR-T Clinical Development, Current State, Challenges of Current State and Potential Solutions | Joseph P. McGuirk, DO  
Professor of Medicine  
Schutte-Speas Professor of Hematology-Oncology  
Medical Director, BMT and Cellular Therapeutics  
Division Director, Hematologic Malignancies and Cellular Therapeutics  
The University of Kansas Cancer Center |
| 1:45 PM| Question and Answer Session                                                                 | Bin He, PhD  
Associate Professor of Transplant Immunology in Surgery, Academic Institute  
Associate Member, Research Institute  
Houston Methodist  
Weill Cornell Medical College |
| 1:55 PM| From Bench to Bedside: The History and Progress of CAR T-Cell Therapy                       | Siddhartha Ganguly, MD, FACP  
Carol Cockrell Curran Distinguished Centennial Chief in Hematologic Oncology, Dr. Mary and Ron Neal Cancer Center  
Professor of Clinical Medicine, Academic Institute  
Full Clinical Member, Research Institute  
Houston Methodist  
Weill Cornell Medical College |
| 2:25 PM| Question and Answer Session                                                                 |                                                                         |
| 2:30 PM| Break and Exhibits                                                                           |                                                                         |
| 2:45 PM| Tumor-Infiltrating Lymphocytes (TIL) for Clinicians                                         | Siddhartha Ganguly, MD, FACP  
Carol Cockrell Curran Distinguished Centennial Chief in Hematologic Oncology, Dr. Mary and Ron Neal Cancer Center  
Professor of Clinical Medicine, Academic Institute  
Full Clinical Member, Research Institute  
Houston Methodist  
Weill Cornell Medical College |
| 3:15 PM| Question and Answer Session                                                                 |                                                                         |
| 3:20 PM| Break and Exhibits                                                                           |                                                                         |
| 3:40 PM| Abstract Winner Discussions                                                                  |                                                                         |
| 4:30 PM| Question and Answer Session                                                                 |                                                                         |
| 4:45 PM| Adjournment                                                                                  |                                                                         |
ACCREDITATION AND CREDIT DESIGNATION STATEMENTS

Physicians
Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Houston Methodist designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Houston Methodist is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Houston Methodist will provide 6.0 contact hours for this activity. Participants must attend the activity in its entirety and complete the corresponding evaluation.

HOW TO RECEIVE YOUR CERTIFICATE
After the activity, an email will be sent from https://learn.houstonmethodist.org/ containing a link to the evaluation. Once you complete the evaluation, you will be prompted to claim your credit and print/download your certificate.

CONTACT INFORMATION
Office of Continuing Medical Education
Houston Methodist Hospital
6670 Bertner Avenue, R2-216
Houston, TX 77030
Phone: 713.441.4971
Fax: 713.441.0589
Email: cme@houstonmethodist.org

DISCLAIMER AND DISCLOSURES
Houston Methodist makes every effort to develop continuing education activities that are scientifically based, accurate, current, and objectively presented. In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education and American Nurse Credentialing Center (ANCC) and Accreditation Council for Pharmacy Education (ACPE) guidelines, Houston Methodist has implemented a mechanism requiring everyone in a position to control content of an educational activity (e.g., directors, planning committee members, contributors, peer reviewers, etc.) to disclose all financial relationships with ineligible companies (companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) and mitigate any relevant financial relationships prior to the activity. Individuals must disclose to participants the existence of financial relationships at the time of the activity and 24 months prior.

Houston Methodist does not view the existence of interests or relationships with ineligible companies as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.

In addition, if contributors will be discussing products (drugs/devices) they have been instructed to use generic names and to include various products within and across classes. If at any time during this activity you feel that there has been commercial or promotional bias, please notify the CE coordinator for the activity and note your comments by using the commercial bias comments box in the evaluation form. Please answer the question about balance in the CE activity evaluation candidly.

Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with applicable law.

Faculty members are also asked to disclose any unlabeled use or investigational use (not yet approved for any purpose) or pharmaceutical and medical device products and provide adequate scientific and clinical justification for such use. Physicians are urged to fully review all the available data on products or procedures before using them to treat patients.

All the relevant financial relationships listed for these individuals have been mitigated.

<table>
<thead>
<tr>
<th>Name</th>
<th>Role(s)</th>
<th>Relevant Financial Relationship(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nakul Gupta, MD</td>
<td>Speaker</td>
<td>Consultant: GE Healthcare</td>
</tr>
<tr>
<td>Maha Hussain, MD, FACP, FASCO</td>
<td>Speaker</td>
<td>Advisor: GSK, Novartis, Bayer Research: AstraZeneca, Genentech, Bayer, Arvinas</td>
</tr>
<tr>
<td>Joseph McGuirk, DO</td>
<td>Speaker</td>
<td>Consultant: Kite, AlloVir, Bristol Myers Squibb, Novartis, CRISPR Therapeutics, Nektar, Sana, Caribou Bio, Legend Biotech</td>
</tr>
</tbody>
</table>

All other individuals in control of content of this activity have no relevant financial relationships with ineligible companies to disclose.
EXHIBITORS

We gratefully acknowledge the following companies for participating as exhibitors for this activity:

AbbVie
Amgen
Astellas Pharma
AstraZeneca
BeiGene
CTI Biopharma
Eli Lilly and Company
Incyte Corporation
Janssen Pharmaceuticals
Jazz Pharmaceuticals
Merck

Morphosys
Myovant
Novartis
Pfizer
Pharmacyclics (PCYC)
Regeneron
Rigel Pharmaceuticals
Sanofi-Genzyme
Taiho
Takeda